Equities

Medicenna Therapeutics Corp

MDNAF:QBB

Medicenna Therapeutics Corp

Actions
  • Price (USD)1.52
  • Today's Change-0.02 / -1.30%
  • Shares traded19.03k
  • 1 Year change+408.36%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 20:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in CAD

The one analyst offering a 12 month price target expects Medicenna Therapeutics Corp share price to rise to 2.51 in the next year from the last price of 1.52.
High65.0%2.51
Med65.0%2.51
Low65.0%2.51

Earnings history & estimates in CAD

On Jul 30, 2024, Medicenna Therapeutics Corp reported 1st quarter 2025 losses of -0.05 per share. This result was in line with the expectation of the one analyst following the company and under-performed last year's 1st quarter results by 25.00%.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate-43.93%
Medicenna Therapeutics Corp reported annual 2024 losses of -0.37 per share on Jun 27, 2024.
Average growth rate-29.52%
More ▼

Revenue history & estimates in CAD

-32768 did not report revenues for the 1st quarter 2025. However, during the 1st quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
-32768 did not report revenues for the full year 2024. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.